Does it look today like the big multibaggers (×10, ×100) did when they started? 7 traits measured with public data.
Strongest: Balance sheet and Price vs. growth. Most lacking: Room to grow and Cash it generates.
Worth $99.4 B. To grow ×10 it would have to reach $994 B.
Sales +36% last quarter (year over year) and +1% last fiscal year · accelerating.
Gross margin 47%, operating margin 40%, return on equity 15%.
Free cash flow $2.6 B a year = 2.6% of its value.
Trades at 5.9× sales: 0.32 per point of growth (lower is better).
Net cash equal to 7% of its value.
Government contracts with firm money = 0.3% of its value · inside a Faro megatrend · insiders own 2.1%.
⏱️ Timing (not scored): near its 12-month high · above its 200-day average · beating the S&P 500 by 34 points over 12 months.
Built on the traits of 365 stocks that went ×100 (Mayer, 1962–2014) and 464 that went ×10 (Yartseva, 2009–2024), plus the Faro thesis. It does not predict the price and is not a recommendation. How it works and the ranking →
The last 12 months, in plain words
Directional bias · probability of rising · expected price and likely range (68%)
| Horizon | Bias | Prob. up | Expected price | 68% range |
|---|---|---|---|---|
| 1 day | Strongly bullish | 63% | $961.55 +0.0% | $940.04 – $983.54 |
| 3 days | Strongly bullish | 63% | $962.12 +0.1% | $925.16 – $1,000.56 |
| 1 week | Strongly bullish | 64% | $962.69 +0.1% | $915.21 – $1,012.63 |
| 15 days | Strongly bullish | 65% | $964.12 +0.3% | $897.57 – $1,035.60 |
| 1 month | Strongly bullish | 65% | $967.27 +0.6% | $872.04 – $1,072.91 |
| 3 months | Strongly bullish | 65% | $979.42 +1.9% | $818.47 – $1,172.01 |
Recent momentum: +32.3% over 20 days · +22.6% over 60 days. The further out the horizon, the wider and more uncertain the forecast.
The public money behind this company — the "Follow the Contract" pattern.
Inmazeb ebola therapeutics
💡 Worth 0.28% of the company's market value. Firm money at signing: $278 M. Stock since the announcement: +22%.
PDF reports built from official filings. Your first one is free, no email; then $1.99 each or all 33 for $25 — included in Navigator and Admiral.
The market's memory: 100 years of crashes and recoveriesSince 1927 the S&P 500 has fallen more than 20% about a dozen times. It always recovered, but sometimes it took 25 y…6 pp. · Free preview →
Study: What the big winners had in commonMicron 13x, Carpenter 12x, NVIDIA 9x… We analyze the stocks that rose most in five years within the Faro universe: which…6 pp. · Free preview →
Practical guide: How to read an earnings report in 15 minutesEvery three months companies publish their numbers. The market reacts in seconds. A 7-step method, with real 2026 exampl…6 pp. · Free preview →Its Faro multibagger DNA is 63/100 (promising): it measures how much it looks today like the big multibaggers did when they started (size, sales growth, quality, cash, price versus growth, balance sheet and public contracts). To grow ×10 it would need to be worth about 10 times today's value. Not a prediction or a recommendation.
Regeneron Pharmaceuticals (REGN) is up 47.0% over the last 12 months and trades at $961.26, practically at its 52-week high. 52-week range: $600.66 – $961.26.
Its annualized volatility is around 36% and its worst drop from a peak over the last year was 26.1%. For reference, the S&P 500 usually moves 15–20% a year.
Yes. Faro's register lists 1 contract; the most recent: Health & Human Services, $278 M, Sep 25, 2026.
Nobody can know that for sure and this page is not a buy recommendation. What the data shows today: strongly bullish technical bias, RSI 88 (overbought zone), price above its 50-day average and an estimated 65% probability of being higher in 1 month. Use it as a starting point for research, not as a signal.
The verdict combines trend (20/50/200 moving averages), momentum (RSI, MACD), mean reversion (Bollinger Bands), conviction (volume) and historical drift, weighted differently for each horizon. Uncertainty is modeled with a lognormal probability cone (geometric Brownian motion). This is statistical analysis, not a crystal ball.
Other stocks Faro watches